En­docrine-fo­cused biotech gets new cash for its pep­tides, with dreams of launch­ing a fran­chise

On the hunt for a pipeline that keeps on giv­ing, a vet­er­an group of en­docri­nol­o­gists have earned new back­ers for a biotech it thinks can of­fer a tar­get-rich en­vi­ron­ment for pep­tide drugs.

Amolyt Phar­ma has put to­geth­er an $80 mil­lion Se­ries B, the French-Amer­i­can biotech an­nounced, aim­ing main­ly to push for­ward re­search in­to rare en­docrine dis­eases and its lead pro­gram for hy­poparathy­roidism. The round comes a lit­tle more than two years af­ter the com­pa­ny’s Se­ries A and about two weeks be­fore Amolyt un­veils new da­ta for that lead can­di­date.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER